Mumps is back: Why is mumps eradication not working?

Advances in Experimental Medicine and Biology

Volumn 697, Issue , 2011, Pages 197-220

  MacDonald, Noni ^a,b   Hatchette, Todd ^a   Elkout, Lotfia ^a,b   Sarwal, Shelly ^c  

^a DALHOUSIE UNIVERSITY   (Canada)

^b IWK HEALTH CENTRE   (Canada)

^c Pictou County District Health Authorities   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MUMPS VACCINE;

ARTICLE; ASEPTIC MENINGITIS; AUSTRALIA; CANADA; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; EPIDEMIC; ERADICATION THERAPY; FEVER; FINLAND; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; INJECTION SITE PAIN; INJECTION SITE SWELLING; MASS IMMUNIZATION; MOLECULAR DIAGNOSIS; MUMPS; MUMPS VIRUS; NETHERLANDS; NONHUMAN; PAROTITIS; PERCEPTION DEAFNESS; PRIORITY JOURNAL; SEROLOGY; SINGLE DRUG DOSE; TISSUE CULTURE; TREATMENT REFUSAL; UNITED KINGDOM; UNITED STATES; VACCINE FAILURE; VIRUS PATHOGENESIS; VIRUS REPLICATION; VIRUS TRANSMISSION; VIRUS VIRULENCE; CHILD; DISEASE TRANSMISSION; GROWTH, DEVELOPMENT AND AGING; REVIEW;

CHILD; COMMUNICABLE DISEASE CONTROL; EPIDEMICS; HUMANS; MUMPS; MUMPS VACCINE; MUMPS VIRUS;

EID: 79952276463     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-7185-2_14     Document Type: Article

References (92)

1. Habel K. Vaccination of human beings against mumps; vaccine administered at the start of an epidemic. I. Incidence and severity of mumps in vaccinated and control groups. Am J Hyg. 1951;54(3):295-311.
2. World Health Organization. Mumps virus vaccines. Wkly Epidemiol Rec. 2007;82(7):51-60.
3. Fullerton KE, Reef SE. Commentary Ongoing debate over the safety of the different mumps vaccine strains impacts mumps disease control. Int J Epidemiol. 2002;31(5):983-4.
4. Health Protection Agency. Continued increase in mumps in universities 2008/2009 News; 2009 April. http://www.hpa.org.uk/hpr/archives/2009/news1409.htm
5. Sartorius B, Penttinen P, Nilsson J, Johansen K, Jonsson K, Arneborn M et al. An outbreak of mumps in Sweden, Feb-Apr 2004. Euro Surveill. 2005;10(9):191-3. http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=559 .
6. Karagiannis I, van Lier A, van Binnendijk R, Ruijs H, Ruijs H, Fanoy E et al. Mumps in a community with low vaccination coverage in the Netherlands. Euro Surveill. 2008;13(24). http://www.eurosurveillance.org/ViewArticle.aspx? ArticleId=18901 .
7. Watson-Creed G, Saunders A, Scott J, Lowe L, Pettipas J, Hatchette TF. Two successive outbreaks of mumps in Nova Scotia among vaccinated adolescents and young adults. CMAJ. 2006;175(5):483-8.
8. Aratchige PE, McIntyre PB, Quinn HE, Gilbert GL. Recent increases in mumps incidence in Australia: the "forgotten" age group in the 1998 Australian measles control campaign. Med J Aust. 2008;189(8):434-7.
9. Dayan GH, Quinlisk MP, Parker AA, Barskey AE, Harris ML, Schwartz JM et al. Recent resurgence of mumps in the United States. N Engl J Med. 2008;358(15):1580-9.
10. Vandermeulen C, Roelants M, Vermoere M, Roseeuw K, Goubau P, Hoppenbrouwers K. Outbreak of mumps in a vaccinated child population: a question of vaccine failure? Vaccine. 2004;22(21-22):2713-16.
11. Peltola H, Jokinen S, Paunio M, Hovi T, Davidkin I. Measles, mumps, and rubella in Finland: 25 years of a nationwide elimination programme. Lancet Infect Dis. 2008;8(12):796-803.
12. Vandermeulen C, Leroux-Roels G, Hoppenbrouwers K. Mumps outbreaks in highly vaccinated populations: What makes good even better?. Hum Vaccin. 2009;5(7):494-6.
13. Galazka AM, Robertson SE, Kraigher A. Mumps and mumps vaccine: a global review. Bull World Health Organ. 1999;77(1):3-14.
14. Hviid A, Rubin S, Muhlemann K. Mumps. Lancet. 2008;371(9616):932-44.
15. Agarwal T, Rahman N, Abel R. Down in the mumps. J Pediatr Surg. 2006;41(12):e17-18.
16. Hashimoto H, Fujioka M, Kinumaki H. An office-based prospective study of deafness in mumps. Pediatr Infect Dis J. 2009;28(3):173-5.
17. Baas MC, van Donselaar KA, Florquin S, van Binnendijk RS, ten Berge IJ, Bemelman FJ. Mumps: not an innocent bystander in solid organ transplantation. Am J Transplant. 2009;9(9):2186-9.
18. Plotkin SA, Rubin SA. Mumps vaccine. In: SA Plotkin WA Orenstein, PA Offit editors. Vaccines. 5th ed. Philadelphia, PA: Elsevier; 2008. p. 435-65.
19. Ornoy A, Tenenbaum A. Pregnancy outcome following infections by coxsackie, echo, measles, mumps, hepatitis, polio and encephalitis viruses. Reprod Toxicol. 2006;21(4): 446-57.
20. Anderson LJ, Seward JF. Mumps epidemiology and immunity: the anatomy of a modern epidemic. Pediatr Infect Dis J. 2008;27(10 Suppl):S75-S79.
21. Rubin SA, Amexis G, Pletnikov M, Li Z, Vanderzanden J, Mauldin J et al. Changes in mumps virus gene sequence associated with variability in neurovirulent phenotype. J Virol. 2003;77(21):11616-24.
22. Rubin SA, Afzal MA, Powell CL, Bentley ML, Auda GR, Taffs RE et al. The rat-based neurovirulence safety test for the assessment of mumps virus neurovirulence in humans: an international collaborative study. J Infect Dis. 2005;191(7):1123-8.
23. Johansson B, Tecle T, Orvell C. Proposed criteria for classification of new genotypes of mumps virus. Scand J Infect Dis. 2002;34(5):355-7.
24. Dayan GH, Rubin S. Mumps outbreaks in vaccinated populations: are available mumps vaccines effective enough to prevent outbreaks?. Clin Infect Dis. 2008;47(11):1458-67.
25. Friedman M, Hadari I, Goldstein V, Sarov I. Virus-specific secretory IgA antibodies as a means of rapid diagnosis of measles and mumps infection. Isr J Med Sci. 1983;19(10):881-4.
26. Friedman MG. Radioimmunoassay for the detection of virus-specific IgA antibodies in saliva. J Immunol Methods. 1982;54(2):203-11.
27. Simpson RE. Infectiousness of communicable diseases in the household (measles, chickenpox, and mumps). Lancet. 1952;2(6734):549-54.
28. World Health Organization. WHO-recommended standards for surveillance of selected vaccine-preventable diseases Geneva; 2003. http://www.who.int/ immunization-monitoring/ diseases/mumps-surveillance/en/
29. Davidkin I, Jokinen S, Paananen A, Leinikki P, Peltola H. Etiology of mumps-like illnesses in children and adolescents vaccinated for measles, mumps, and rubella. J Infect Dis. 2005;191(5):719-23.
30. Brook I. Diagnosis and management of parotitis. Arch Otolaryngol Head Neck Surg. 1992;118(5):469-71.
31. Bastien N, Bowness D, Burton L, Bontovics E, Winter AL, Tipples G et al. Parotitis in a child infected with triple-reassortant influenza A virus in Canada in 2007. J Clin Microbiol. 2009;47(6):1896-8.
32. Falk WA, Buchan K, Dow M, Garson JZ, Hill E, Nosal M et al. The epidemiology of mumps in southern Alberta 1980-1982. Am J Epidemiol. 1989;130(4):736-49.
33. CDC (Atlanta) http://www.cdc.gov/ncphi/disss/nndss/casedef/mumps-2008.htm last accessed 10 Sep, 2009.
34. Leland DS. Parainfluenza and mumps viruses. In: PR Murray, EJ Baron, JH Jorgensen, ML Landry and MA Pfaller (ed.). Manual of Clinical Microbiology. 2007; 9:1352-60; Washington, DC: ASM Press.
35. Krause CH, Eastick K, Ogilvie MM. Real-time PCR for mumps diagnosis on clinical specimens-comparison with results of conventional methods of virus detection and nested PCR. J Clin Virol. 2006;37:184-9.
36. Hatchette TF, Davidson R, Clay S, Pettipas J, LeBlanc J, Sarwal S, Smieja M, Forward KR. Laboratory diagnosis of mumps in a partially immunized population: The Nova Scotia Experience. Can J Infect Dis Med Microbiol. 2009;20(4):e157-e162.
37. CDC (Atlanta) http://www.cdc.gov/ncphi/disss/nndss/casedef/mumps-2008.htm last accessed 10 Sep 2009.
38. Germann D, Gorgievski A, Strohle A, Matter L. Detection of mumps virus in clinical specimens by rapid centrifugation culture and conventional tube cell culture. J Virol Methods. 1998;73:59-64.
39. Uchida K, Shinohara M, Shimada S, Segawa Y, Doi R, Gotoh A, Hondo R. Rapid and sensitive detection of mumps virus RNA directly from clinical samples by real-time PCR. J Med Virol. 2005;75:470-4.
40. Jin L, Beard S, Brown DW. Genetic heterogeneity of mumps virus in the United Kingdom: identification of two new genotypes. J Infect Dis. 1999;180:829-33.
41. Boddicker JD, Rota PA, Kreman T, Wangeman A, Lowe L, Hummel KB, Thompson R, Bellini WJ, Pentella M, Desjardin LE. Real-time reverse transcription-PCR assay for detection of mumps virus RNA in clinical specimens. J Clin Microbiol. 2007;45: 2902-8.
42. Leblanc JJ, Pettipas J, Davidson RJ, Tipples GA, Hiebert J, Hatchette TF. Detection of mumps virus RNA by real-time one-step reverse transcriptase PCR using the LightCycler platform. J Clin Microbiol. 2008;46:4049-51.
43. Jin L, Feng Y, Parry R, Cui A, Real-time LuY. PCR and its application to mumps rapid diagnosis. J Med Virol. 2007;79:1761-7.
44. Krause CH, Molyneaux PJ, Ho-Yen DO, McIntyre P, Carman WE, Templeton. KE. J Clin Virol. 2007;38:153.
45. Rota JS, Turner JC, Yost-Daljev MK, Freeman M, Toney DM, Meisel E, Williams N, Sowers SB, Lowe L, Rota PA, Nicolai LA, Peake L, Bellini WJ. Investigation of a mumps outbreak among university students with two measles-mumps-rubella (MMR) vaccinations, Virginia, September-December 2006. J Med Virol. 2009;81:1819-25.
46. Pipkin PA, Afzal MA, Heath AB, Minor PD. Assay of humoral immunity to mumps virus. J Virol Methods. 1999;79:219-25.
47. Ballew HC. In: S Specter, RL Hodinka, SA Young editors. Neutralization in: clinical virology manual, 3rd ed. Washington, DC. ASM Press, 2000. p. 127-34.
48. Tipples GA, Beirnes J, Hiebert J, Hatchette T, Pettipas J, Macey J, Deeks S, Lipskie T, Bellini W, Rota P, Rota J Laboratory Guidelines for the diagnosis of mumps v.3 (3 Apr 2008) http://www.nml-lnm.gc.ca/guide/guideview-eng.asp?key= 186 (Last accessed 10 Sep 2009:1352-1360).
49. Jick H, Chamberlin DP, Hagberg KW. The origin and spread of a mumps epidemic: United kingdom, 2003-2006. Epidemiology. 2009;20(5):656-61.
50. Muhlemann K. The molecular epidemiology of mumps virus. Infect Genet Evol. 2004;4(3):215-19.
51. Bonnet MC, Dutta A, Weinberger C, Plotkin SA. Mumps vaccine virus strains and aseptic meningitis. Vaccine. 2006;24(49-50):7037-45.
52. World Health Organization. Mumps virus vaccines. Wkly Epidemiol Rec. 2007;82(7):51-60.
53. Stokes J Jr, Weibel RE, Buynak EB, Hilleman MR. Live attenuated mumps virus vaccine. II. Early clinical studies. Pediatrics. 1967;39(3):363-71.
54. Asatryan A, Pool V, Chen RT, Kohl KS, Davis RL, Iskander JK. Live attenuated measles and mumps viral strain-containing vaccines and hearing loss: Vaccine Adverse Event Reporting System (VAERS), United States, 1990-2003. Vaccine. 2008;26(9):1166-72.
55. Kaic B, Gjenero-Margan I, Aleraj B, Ljubin-Sternak S, Vilibic-Cavlek T, Kilvain S et al. Transmission of the L-Zagreb mumps vaccine virus, Croatia, 2005-2008. Euro Surveill. 2008;13(16). http://www.eurosurveillance.org/ ViewArticle.aspx?ArticleId=18843 .
56. Tesovic G, Poljak M, Lunar MM, Kocjan BJ, Seme K, Vukic BT et al. Horizontal transmission of the Leningrad-Zagreb mumps vaccine strain: a report of three cases. Vaccine. 2008;26(16):1922-5.
57. Atrasheuskaya AV, Neverov AA, Rubin S, Ignatyev GM. Horizontal transmission of the Leningrad-3 live attenuated mumps vaccine virus. Vaccine. 2006;24(10):1530-6.
58. Weibel RE, Stokes J Jr, Buynak EB, Whitman JE Jr, Hilleman MR. Live attenuated mumpsvirus vaccine. 3. Clinical and serologic aspects in a field evaluation. N Engl J Med. 1967;276(5):245-51.
59. Miller E, GoldacreM, Pugh S, Colville A, Farrington P, Flower A et al. Risk of aseptic meningitis after measles, mumps, and rubella vaccine in UK children. Lancet. 1993;341(8851): 979-82.
60. LeBaron CW, Forghani B, Beck C, Brown C, Bi D, Cossen C et al. Persistence of mumps antibodies after 2 doses of measles-mumps-rubella vaccine. J Infect Dis. 2009;199(4): 552-60.
61. Miller E, Hill A, Morgan-Capner P, Forsey T, Rush M. Antibodies to measles, mumps and rubella in UK children 4 years after vaccination with different MMR vaccines. Vaccine. 1995;13(9):799-802.
62. Davidkin I, Jokinen S, Broman M, Leinikki P, Peltola H. Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up. J Infect Dis. 2008;197(7):950-6.
63. Jokinen S, Osterlund P, Julkunen I, Davidkin I. Cellular immunity to mumps virus in young adults 21 years after measles-mumps-rubella vaccination. J Infect Dis. 2007;196(6): 861-7.
64. Harling R, White JM, Ramsay ME, Macsween KF, van den Bosch C. The effectiveness of the mumps component of the MMR vaccine: a case control study. Vaccine. 2005;23(31): 4070-4.
65. Peltola H, Kulkarni PS, Kapre SV, Paunio M, Jadhav SS, Dhere RM. Mumps outbreaks in Canada and the United States: time for new thinking on mumps vaccines. Clin Infect Dis. 2007;45(4):459-66.
66. Beck M, Welsz-Malecek R, Mesko-Prejac M, Radman V, Juzbasic M, Rajninger-Miholic M et al. Mumps vaccine L-Zagreb, prepared in chick fibroblasts. I. Production and field trials. J Biol Stand. 1989;17(1):85-90.
67. Vesikari T, Sadzot-Delvaux C, Rentier B, Gershon A. Increasing coverage and efficiency of measles, mumps, and rubella vaccine and introducing universal varicella vaccination in Europe: a role for the combined vaccine. Pediatr Infect Dis J. 2007;26(7):632-8.
68. Boxall N, Kubinyiova M, Prikazsky V, Benes C, Castkova J. An increase in the number of mumps cases in the Czech Republic, 2005-2006. Euro Surveill. 2008;13(16). http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=18842 .
69. Bernard H, Schwarz NG, Melnic A, Bucov V, Caterinciuc N, Pebody RG et al. Mumps outbreak ongoing since October 2007 in the Republic of Moldova. Euro Surveill. 2008;13(13). http://www.eurosurveillance.org/ViewArticle.aspx? ArticleId=8079 .
70. Kaaijk P, van der Zeijst B, Boog M, Hoitink C. Increased mumps incidence in the Netherlands: review on the possible role of vaccine strain and genotype. Euro Surveill. 2008;13(26). http://www.eurosurveillance.org/ViewArticle.aspx? ArticleId=18914 .
71. Public Health Agency of Canada. Canadian National Report on Immunization, 2006. http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/06vol32/32s3/4epi-eng.php
72. Gay N, Miller E, Hesketh L, Morgan-Capner P, Ramsay M, Cohen B et al. Mumps surveillance in England andWales supports introduction of two dose vaccination schedule. Commun Dis Rep CDR Rev. 1997;7(2):R21-R26.
73. Anderson RM, Crombie JA, Grenfell BT. The epidemiology of mumps in the UK: a preliminary study of virus transmission, herd immunity and the potential impact of immunization. Epidemiol Infect. 1987;99(1):65-84.
74. Colville A, Pugh S, Miller E. Withdrawal of a mumps vaccine. Eur J Pediatr. 1994;153(6):467-8.
75. Centers for Disease Control and Prevention. Mumps epidemic-United kingdom, 2004-2005. MMWR Morb Mortal Wkly Rep. 2006;55(7):173-5.
76. Savage E, Ramsay M, White J, Beard S, Lawson H, Hunjan R et al. Mumps outbreaks across England and Wales in 2004: observational study. BMJ. 2005;330(7500):1119-20.
77. MacDonald N, Flegel K. Mumps in young adults: the canary in the coal mine. CMAJ. 2007;177(2):121, 3.
78. Wright JA, Polack C. Understanding variation in measles-mumps-rubella immunization coverage-a population-based study. Eur J Public Health. 2006;16(2):137-42.
79. Cohen C, White JM, Savage EJ, Glynn JR, Choi Y, Andrews N et al. Vaccine effectiveness estimates, 2004-2005 mumps outbreak, England. Emerg Infect Dis. 2007;13(1):12-17.
80. Gabutti G, Guido M, Rota MC, De Donno A, Ciofi Degli Atti ML, Crovari P. The epidemiology of mumps in Italy. Vaccine. 2008;26(23):2906-11.
81. Public Health Agency of Canada. Mumps in Canada, 2007. 2009. http://www.phac-aspc. gc.ca/mumps-oreillons/prof-eng.php
82. Goh KT. Resurgence of mumps in Singapore caused by the Rubini mumps virus vaccine strain. Lancet. 1999;354(9187):1355-6.
83. Ong G, Goh KT, Ma S, Chew SK. Comparative efficacy of Rubini, Jeryl-Lynn and Urabe mumps vaccine in an Asian population. J Infect. 2005;51(4):294-8.
84. Richard JL, Zwahlen M, Feuz M, Matter HC. Comparison of the effectiveness of two mumps vaccines during an outbreak in Switzerland in 1999 and 2000: a case-cohort study. Eur J Epidemiol. 2003;18(6):569-77.
85. Cortese MM, Jordan HT, Curns AT, Quinlan PA, Ens KA, Denning PM et al. Mumps vaccine performance among university students during a mumps outbreak. Clin Infect Dis. 2008;46(8):1172-80.
86. Rubin SA, Qi L, Audet SA, Sullivan B, Carbone KM, Bellini WJ et al. Antibody induced by immunization with the Jeryl Lynn mumps vaccine strain effectively neutralizes a heterologous wild-type mumps virus associated with a large outbreak. J Infect Dis. 2008;198(4): 508-15.
87. Narita M, Matsuzono Y, Takekoshi Y, Yamada S, Itakura O, Kubota M et al. Analysis of mumps vaccine failure by means of avidity testing for mumps virus-specific immunoglobulin G. Clin Diagn Lab Immunol. 1998;5(6):799-803.
88. Peltola H, Davidkin I, Paunio M, Valle M, Leinikki P, Heinonen OP. Mumps and rubella eliminated from Finland. JAMA. 2000;284(20):2643-7.
89. Centers for Disease Control and Prevention. Updated recommendations for isolation of persons with mumps. MMWR Morb Mortal Wkly Rep. 2008;57(40):1103-5.
90. Marienau KJ, Averhoff F, Redd S. The role of air travel in the spread of mumps. Clin Infect Dis. 2008;47(9):1237.
91. Centers for Disease Control and Prevention. Vaccines & Immunizations. Programs & Tools. CDC Vaccine Price List. 2009. http://www.cdc.gov/ vaccines/programs/vfc/cdc-vac-pricelist. htm
92. Kamerow D. Yankee doodling: jabbering about jabs. BMJ. 2008;337:a1517.